Immunotherapy combo shows promise in bladder cancer trial

NCT ID NCT06960577

Recruiting now Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy before and after bladder cancer surgery is safe and effective. About 150 people with muscle-invasive bladder cancer will receive durvalumab plus either ddMVAC or gemcitabine/cisplatin chemo before surgery, then durvalumab alone after. The goal is to see if this combination reduces side effects and improves outcomes in a real-world setting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Durvalumab (an immunotherapy drug) plus chemotherapy (ddMVAC or gemcitabine/cisplatin)
What this could lead to: If successful, this could show that adding durvalumab to standard chemo before and after bladder cancer surgery improves safety and effectiveness, potentially leading to a new standard treatment.
What could go wrong: This is an early-phase, single-arm study with no placebo group, so results may not be definitive. Side effects from combining immunotherapy and chemotherapy can be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

infiltrating bladder urothelial carcinoma urinary bladder neoplasm Urinary Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CISPLATIN DOXORUBICIN GEMCITABINE IMMUNE CHECKPOINT INHIBITORS METHOTREXATE URINARY BLADDER NEOPLASMS VINBLASTINE

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Research Site
RECRUITING

Chermside, 4032, Australia
Research Site
RECRUITING

Elizabeth Vale, 5112, Australia
Research Site
RECRUITING

Heidelberg, 3084, Australia
Research Site
RECRUITING

Hong Kong, Australia
Research Site
RECRUITING

Kogarah, 2217, Australia
Research Site
RECRUITING

Macquarie University, 2109, Australia
Research Site
RECRUITING

Murdoch, 6150, Australia
Research Site
RECRUITING

Port Macquarie, 2444, Australia
Research Site
RECRUITING

St Leonards, 2065, Australia
Research Site
RECRUITING

Barretos, 14784-400, Brazil
Research Site
WITHDRAWN

Jaú, 17210-080, Brazil
Research Site
WITHDRAWN

Natal, 59075-740, Brazil
Research Site
RECRUITING

Porto Alegre, 91350-200, Brazil
Research Site
WITHDRAWN

Rio de Janeiro, 20230-130, Brazil
Research Site
RECRUITING

Santo André, 09060-650, Brazil
Research Site
WITHDRAWN

São José do Rio Preto, 15090-000, Brazil
Research Site
RECRUITING

São Paulo, 01246-000, Brazil
Research Site
RECRUITING

Hamilton, Ontario, L8V 5C2, Canada
Research Site
NOT_YET_RECRUITING

London, Ontario, N6A 5W9, Canada
Research Site
WITHDRAWN

Ottawa, Ontario, K1H 8L6, Canada
Research Site
NOT_YET_RECRUITING

Montreal, Quebec, H3T 1E2, Canada
Research Site
RECRUITING

Québec, Quebec, G1J 1Z4, Canada
Research Site
RECRUITING

Sherbrooke, Quebec, J1H 5N4, Canada
Research Site
NOT_YET_RECRUITING

Angers, 49055, France
Research Site
WITHDRAWN

Angers, 49933, France
Research Site
NOT_YET_RECRUITING

Bordeaux, 33075, France
Research Site
NOT_YET_RECRUITING

Chambray-lès-Tours, 37170, France
Research Site
NOT_YET_RECRUITING

Dijon, 21079, France
Research Site
NOT_YET_RECRUITING

Lille, 59037, France
Research Site
NOT_YET_RECRUITING

Lyon, 69008, France
Research Site
NOT_YET_RECRUITING

Marseille, 13009, France
Research Site
NOT_YET_RECRUITING

Montpellier, 34070, France
Research Site
NOT_YET_RECRUITING

Nice, 06189, France
Research Site
NOT_YET_RECRUITING

Nîmes, 30029, France
Research Site
NOT_YET_RECRUITING

Paris, 75010, France
Research Site
NOT_YET_RECRUITING

Paris, 75900, France
Research Site
NOT_YET_RECRUITING

Pierre-Bénite, 69310, France
Research Site
NOT_YET_RECRUITING

Poitiers, 86021, France
Research Site
NOT_YET_RECRUITING

Quint-Fonsegrives, 31130, France
Research Site
NOT_YET_RECRUITING

Rennes, 35000, France
Research Site
NOT_YET_RECRUITING

Rouen, 76230, France
Research Site
NOT_YET_RECRUITING

Strasbourg, 67033, France
Research Site
NOT_YET_RECRUITING

Suresnes, 92150, France
Research Site
NOT_YET_RECRUITING

Florence, 50139, Italy
Research Site
NOT_YET_RECRUITING

Orbassano, 10043, Italy
Research Site
NOT_YET_RECRUITING

Roma, 00144, Italy
Research Site
NOT_YET_RECRUITING

Amsterdam, 1066CX, Netherlands
Research Site
NOT_YET_RECRUITING

Nijmegen, 6500 HB, Netherlands
Research Site
NOT_YET_RECRUITING

Rotterdam, 3015 GD, Netherlands
Research Site
NOT_YET_RECRUITING

Barcelona, 08025, Spain
Research Site
NOT_YET_RECRUITING

Barcelona, 08035, Spain
Research Site
NOT_YET_RECRUITING

Barcelona, 08036, Spain
Research Site
NOT_YET_RECRUITING

Barcelona, 8003, Spain
Research Site
NOT_YET_RECRUITING

Girona, 17007, Spain
Research Site
NOT_YET_RECRUITING

Las Palmas de Gran Canaria, 35016, Spain
Research Site
NOT_YET_RECRUITING

Lugo, 27003, Spain
Research Site
NOT_YET_RECRUITING

Madrid, 28033, Spain
Research Site
NOT_YET_RECRUITING

Madrid, 28040, Spain
Research Site
NOT_YET_RECRUITING

Santiago de Compostela, 15706, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.